Kidney replacement and conservative therapies in rhabdomyolysis: a retrospective analysis

BMC Nephrology

Table 4 Hospital mortality and specific kidney replacement therapies (univariate analysis)

	All n = 171	CVVH n = 41	CVVHD-HCO n = 44	CVVHD-adsorber n = 9	CVVHDF n = 14	CVVHD/SLEDD n = 48	p
Hospital mortality	95 (55.6%)	16 (39.0%)	25 (56.8%)	6 (66.7%)	11 (78.6%)	30 (62.5%)	0.015^*
APACHE II	32 [7;14]	29 [24;36]	34 [25;39]	30 [26;33]	33 [27;40]	33 [26;40]
SOFA	11 (7;14)	9 [5;13]	10 [7;14]	11 [9;15]	13 [9;16]	12 [7;14]
Predicted mortality^a	56.7%	45.8%	63.7%	49.5%	60.3%	60.3%

APACHE Acute Physiology And Chronic Health Evaluation, CVVH Continuous veno-venous hemofiltration, CVVHD Continuous veno-venous hemodialysis, CVVHDF Continuous veno-venous hemodiafiltration, HCO High cut-off, SLEDD Sustained low-efficiency daily dialysis, SOFA Sequential organ failure assessment
^*Chi-square test: CVVH vs. all other KRT modalities
^aPredicted mortality based on Apache II score (reason for admission: metabolic/renal (https://clincalc.com/IcuMortality/) [31])

ISSN: 1471-2369